Type 2 Diabetes Mellitus
📧 Sign up to get email alerts when something new happens for Type 2 Diabetes Mellitus.
Sign up freeTop drugs studied for this disease
-
FDA approval · 2023-10-30FDA Approved: GLYXAMBI — Supplemental Application (Boehringer Ingelheim Pharmaceuticals, Inc.)
FDA approved a supplemental application for GLYXAMBI (empagliflozin and linagliptin) from Boehringer Ingelheim Pharmaceuticals, Inc.
-
FDA approval · 2023-10-30FDA Approved: SYNJARDY XR — Supplemental Application (Boehringer Ingelheim Pharmaceuticals, Inc.)
FDA approved a supplemental application for SYNJARDY XR (empagliflozin/metformin hydrochloride) from Boehringer Ingelheim Pharmaceuticals, u…
-
CLINICAL_TRIALS research · 2023-10-30Clinical Trial Update: The Effect of Omega-3 FA on Hypertriglyceridemia in Patients With T2DM(OCEAN) [Phase 4]
A Phase 4 clinical trial assessing the impact of omega-3 fatty acids on hypertriglyceridemia in patients with type 2 diabetes mellitus.
-
CLINICAL_TRIALS trial_result · 2023-10-25Clinical Trial Update: Remission Evaluation of a Metabolic Intervention for Type 2 Diabetes With IDegLira [Phase 3]
Phase 3 clinical trial evaluating remission of Type 2 diabetes with metabolic intervention using IDegLira; study completed.
-
CLINICAL_TRIALS trial_result · 2023-10-23Clinical Trial Update: A Randomized, Active-controlled, Parallel, Open-label, Multicenter, Phase 4 Study to Compare the Efficacy and Safety of Pregabalin Sustained Release Tablet and Pregabalin Immediate Release Capsule in Type II Diabetic Patients With Peripheral Neuropathic Pain [Phase 4]
Phase 4 randomized study comparing pregabalin sustained release vs immediate release in type 2 diabetes patients with peripheral neuropathic…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2023-10-19Clinical Trial Update: Efficacy and Safety of Dapagliflozin for the Hospital Management of Patients With Type 2 Diabetes [Phase 4]
Phase 4 clinical trial update evaluating the efficacy and safety of dapagliflozin for hospital management in patients with type 2 diabetes, …
-
EMA safety_alert · 2023-10-18EMA alerts EU patients and healthcare professionals to reports of falsified Ozempic pens
EMA warns about reports of falsified Ozempic pens and provides guidance to patients and healthcare professionals to verify authenticity and …
-
FDA approval · 2023-10-18FDA Approved: SITAGLIPTIN — Original Application (Zydus Lifesciences Limited)
FDA approved a sitagliptin product under an Original Application from Zydus Lifesciences Limited for type 2 diabetes mellitus.
-
CLINICAL_TRIALS trial_result · 2023-10-18Clinical Trial Update: A Study of U-500 Insulin (LY041001) in Participants With Type 2 Diabetes [Phase 1]
Phase 1 trial update for U-500 insulin (LY041001) in participants with Type 2 diabetes; study terminated with results posted.
-
CLINICAL_TRIALS trial_result · 2023-10-17Clinical Trial Update: A Study of LY3502970 in Participants With Type 2 Diabetes Mellitus [Phase 2]
Phase 2 trial update for LY3502970 in type 2 diabetes has completed with results posted.
-
CLINICAL_TRIALS trial_result · 2023-10-17Clinical Trial Update: Effect of Akkermansia Muciniphila WST01 Strain in Overweight or Obese Patients With Type 2 Diabetes [Phase 2]
Phase 2 study investigating the effects of Akkermansia muciniphila WST01 in overweight/obese patients with type 2 diabetes; current status i…
-
CLINICAL_TRIALS trial_result · 2023-10-13Clinical Trial Update: Effect of an Extract of Green Tea on Adults With Type 2 Diabetes [Phase 2, Phase 3]
A Phase 2/3 trial assessing an extract of green tea in adults with type 2 diabetes has completed enrollment and/or reporting results.
-
CLINICAL_TRIALS trial_result · 2023-10-12Clinical Trial Update: The Effect of Addition of Metformin to SGLT2 In Diabetic Patients With Heart Failure With Preserved Ejection Fraction [Phase 2, Phase 3]
A phase 2/3 clinical trial evaluating the addition of metformin to SGLT2 inhibitors in patients with type 2 diabetes and heart failure with …
-
CLINICAL_TRIALS trial_result · 2023-10-05Clinical Trial Update: Semaglutide Treatment On Coronary Progression [Phase 4]
A Phase 4 trial update evaluating semaglutide treatment on coronary progression in patients with Type 2 Diabetes and Coronary Artery Disease…
-
FDA approval · 2023-10-05FDA Approved: METFORMIN HYDROCHLORIDE — Original Application (Laurus Labs Limited)
FDA approved Laurus Labs Limited's original application for metformin hydrochloride, a generic version of the diabetes medicine used to trea…
-
FDA approval · 2023-10-04FDA Approved: COLESEVELAM HCL — Supplemental Application (Ascend Laboratories, LLC)
The FDA approved a supplemental application for Colesevelam HCl submitted by Ascend Laboratories, LLC, as part of the generic drug approval …
-
FDA approval · 2023-10-03FDA Approved: GLIPIZIDE — Original Application (Advagen Pharma Limited)
The FDA approved Advagen Pharma Limited's original application for glipizide (generic). It confirms availability of a generic formulation in…
-
CLINICAL_TRIALS trial_result · 2023-09-29Clinical Trial Update: A Research Study Comparing a New Medicine Oral Semaglutide to Sitagliptin in People With Type 2 Diabetes [Phase 3]
A Phase 3 trial comparing oral semaglutide to sitagliptin in Type 2 diabetes has completed, with results posted.
-
FDA approval · 2023-09-28FDA Approved: SOLIQUA 100/33 — Supplemental Application (Sanofi-Aventis U.S. LLC)
FDA approves the supplemental application for SOLIQUA 100/33 (insulin glargine and lixisenatide) from Sanofi-Aventis U.S. LLC.
-
CLINICAL_TRIALS trial_result · 2023-09-28Clinical Trial Update: Pivotal Trial of a Digital Therapeutic for the Treatment of Type 2 Diabetes [Phase 3]
Pivotal Phase 3 trial of a digital therapeutic for Type 2 Diabetes has completed.
-
CLINICAL_TRIALS trial_result · 2023-09-28Clinical Trial Update: Dulce Digital-COVID Aware (DD-CA) Discharge Texting Platform for US/Mexico Border Hispanics With Diabetes + COVID-19 [NA]
Completed clinical trial evaluating a discharge texting platform (DD-CA) for Hispanic patients with type 2 diabetes and COVID-19 along the U…
-
CLINICAL_TRIALS trial_result · 2023-09-28Clinical Trial Update: Multiple-dose Study to Evaluate the Safety,Tolerability, Pharmacokinetics and Pharmacodynamics of HSK7653 in T2DM [Phase 2]
Phase 2 clinical trial evaluating safety, tolerability, pharmacokinetics, and pharmacodynamics of HSK7653 in type 2 diabetes mellitus has co…
-
CLINICAL_TRIALS trial_result · 2023-09-28Clinical Trial Update: Use of an Investigational Digital Therapeutic in Patients With Type 2 Diabetes [Phase 3]
Phase 3 clinical trial update for an investigational digital therapeutic in type 2 diabetes has been terminated.
-
CLINICAL_TRIALS trial_result · 2023-09-26Clinical Trial Update: SITAgliptin Plus GLARgine to Glycemic Control in the Hospital Setting (SITAGLAR-H) [Phase 4]
Phase 4 clinical trial update evaluating SITAgliptin plus GLARgine for glycemic control in hospitalized Type 2 diabetes patients has complet…
-
FDA approval · 2023-09-22FDA Approved: OZEMPIC — Supplemental Application (Novo Nordisk)
FDA approved a supplemental application for Ozempic (semaglutide) from Novo Nordisk.